Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Study findings from University of Louisville, Institute for Cellular Therapeutics broaden understanding of vaccines
December 3rd, 2008
Scientists discuss in 'Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant' new findings in vaccines. "The development of non-infectious subunit vaccines greatly increases the safety of prophylactic immunization, but also reinforces the need for a new generation of immunostimulatory adjuvants. Because adverse effects are a paramount concern in prophylactic immunization, few new adjuvants have received approval for use anywhere in the developed world," investigators in the United States report. "The vaccine adjuvant monophosphoryl lipid A is a detoxified form of the endotoxin lipopolysaccharide, and is among the first of a...
Source: Vaccine Weekly (2008-12-03)
|
